Lifetime Health Optimization
Quant Biomarker is a Swiss life science technology company focused on advancing healthy longevity.
We delivery predictive biomarker-based platforms for early detection and prognostics of chronic diseases and new therapeutic targets.
Company Goals
In a world where people stay healthy while aging, Quant Biomarkers' primary mission is to advance biomarker technologies, predict risks for the onset of chronic diseases to identify targets for personalized medical interventions
We target biology of aging as our foundation for disease prevention
QuantBio combines longitudinal clinical, health records & research data to evaluate multiple dimensions of aging. We complement this data with in-vitro, in-vivo models, proprietary assays and Artificial Intelligence, to deliver tangible guidance for decisions that improve the quality of an individual's lifespan
Who we are
Quant Biomarkers is a data-driven biotechnology company that specialises in quantitative assessment of biomarkers of human longevity and in development of personalised biomarker panels as early targets for interventions in aging diseases
Objective
We work with high-quality longitudinal human data and medical records that enable us to correlate our biological measurements with health outcomes. We use proprietary invitro, in vivo models to determine which pathways are most strongly associated with diseases onset and identify critical intervention targets for healthy longevity
We develop tools that guide and empower medical decision-making, by all the stakeholders in the patient ecosystem
Our company strategic imperative:
Quant Biomarker’s focus is to drive for sustainable, preventive, and scalable digital health solutions for Healthy Lifespan
Our strategic direction is in developing personalised biomarker panels for aging related chronic diseases and selection of endpoints for interventions and multitreatment modalities
Our Deliverables
Proprietary products:
-
AI-based Algorithms for disease risk predictions and early interventions
-
Personalized medical intervention protocols
-
Tissue-specific Biomarker Panels for diagnostic use
-
New Biomarker IP for therapeutics
-
Digital Twin consumer application for Real-Time Data exchange & timely Interventions
Partners
.png)
.png)
